Avalo Board Member Gets $90K Worth of Stock Options in Annual Compensation

Rhea-AI Filing Summary

Avalo Therapeutics director Aaron Kantoff received a new stock option grant on June 17, 2025. The derivative security details include:

• Granted 20,100 stock options to purchase common stock
• Exercise price set at $4.47 per share
• Options will vest 100% on June 17, 2026 (first anniversary of grant date)
• Expiration date is June 17, 2035
• Vesting is contingent on continued service as director

This Form 4 filing was submitted by Donald R. Reynolds via power of attorney on June 18, 2025. The grant appears to be part of the company's director compensation program. The options represent a direct ownership interest and will become exercisable upon vesting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KANTOFF AARON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,100	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,100 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KANTOFF AARON

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.47	06/17/2025		A		20,100		(1)	06/17/2035	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date.

	/s/ Donald R. Reynolds, by Power of Attorney	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to Aaron Kantoff by AVTX on June 17, 2025?

Aaron Kantoff was granted 20,100 stock options with an exercise price of $4.47 per share. These options were granted on June 17, 2025, and will expire on June 17, 2035.

What is the vesting schedule for AVTX director Aaron Kantoff's stock options?

The stock options granted to Aaron Kantoff will vest 100% on the first anniversary of the grant date (June 17, 2026), subject to his continued service as an Eligible Director until the vesting date.

What position does Aaron Kantoff hold at AVTX?

According to the Form 4 filing, Aaron Kantoff serves as a Director of Avalo Therapeutics, Inc. (AVTX). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the total value of stock options granted to AVTX director Kantoff in June 2025?

Aaron Kantoff received 20,100 stock options with a strike price of $4.47 per share. The options were granted at $0 cost to Kantoff, as indicated in the 'Price of Derivative Security' column, representing standard compensation for his role as a director.